Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Acute Kidney in Patients with Cancer
EF 2016-17
Résumé
Acute kidney injury (AKI) is increasingly recognized as a major cause of hospitalization, increased costs, morbidity and mortality. Patients with cancer may be at high risk. While limited data exists, studies estimate one-fifth of patients will have AKI within 1 year of diagnosis. Patients with cancer are susceptible to many forms of kidney injury including chemotherapy, tumour breakdown products and kidney obstruction. The use of chemotherapy at appropriate doses/intervals may be precluded by renal disease, which may worsen outcomes. Patients with kidney disease are excluded from treatment trials and benefits of new therapy may be lost. Despite myriad risks there is little data to characterize the burden of AKI in this group. Few studies have examined AKI by severity, progression to chronic kidney disease or subsequent mortality. It is not known whether AKI results in delay of therapy or reductions in dosing/duration, which may impact survival.Our objective is to use population-level Ontario administrative data to characterize AKI in patients with cancer.Aim 1: Determine the rate of AKI within 1 year of diagnosis of common cancers. We hypothesize patients with cancer will have higher rates of AKI than the general population.Aim 2: Determine associations between common chemotherapies and incidence of AKI, whether AKI results in delay/stop of therapy, and assess risk factors, i.e. co-prescription of other kidney-toxic drugs. We hypothesize AKI will be associated with delay in therapy.Aim 3: Determine the association of AKI and mortality in patients with cancer, and whether AKI associates with increased mortality compared to matched patients without AKI. We hypothesize AKI will associate with decreased survival in patients with cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367189
Name
Kitchlu Abhijat
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Acute Kidney in Patients with Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Kidney Injury; Cancer; Chemotherapy; Chronic Kidney Disease; Clinical Epidemiology; Dialysis; Health Administrative Data; Neoplasm; Onco-Nephrology; Population Health
Abstract
Acute kidney injury (AKI) is increasingly recognized as a major cause of hospitalization, increased costs, morbidity and mortality. Patients with cancer may be at high risk. While limited data exists, studies estimate one-fifth of patients will have AKI within 1 year of diagnosis. Patients with cancer are susceptible to many forms of kidney injury including chemotherapy, tumour breakdown products and kidney obstruction. The use of chemotherapy at appropriate doses/intervals may be precluded by renal disease, which may worsen outcomes. Patients with kidney disease are excluded from treatment trials and benefits of new therapy may be lost. Despite myriad risks there is little data to characterize the burden of AKI in this group. Few studies have examined AKI by severity, progression to chronic kidney disease or subsequent mortality. It is not known whether AKI results in delay of therapy or reductions in dosing/duration, which may impact survival.Our objective is to use population-level Ontario administrative data to characterize AKI in patients with cancer.Aim 1: Determine the rate of AKI within 1 year of diagnosis of common cancers. We hypothesize patients with cancer will have higher rates of AKI than the general population.Aim 2: Determine associations between common chemotherapies and incidence of AKI, whether AKI results in delay/stop of therapy, and assess risk factors, i.e. co-prescription of other kidney-toxic drugs. We hypothesize AKI will be associated with delay in therapy.Aim 3: Determine the association of AKI and mortality in patients with cancer, and whether AKI associates with increased mortality compared to matched patients without AKI. We hypothesize AKI will associate with decreased survival in patients with cancer.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kitchlu, Abhijat
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~